Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Receivables: 2020-2021

Historic Receivables for Mereo BioPharma Group (MREO) over the last 2 years, with Dec 2021 value amounting to $3.0 million.

  • Mereo BioPharma Group's Receivables fell 5.34% to $2.4 million in Q2 2022 from the same period last year, while for Jun 2022 it was $10.4 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2021, which is 28.51% up from last year.
  • Mereo BioPharma Group's Receivables amounted to $3.0 million in FY2021, which was up 28.51% from $2.3 million recorded in FY2020.
  • Mereo BioPharma Group's Receivables' 5-year high stood at $3.0 million during FY2021, with a 5-year trough of $2.3 million in FY2020.
  • Moreover, its 2-year median value for Receivables was $2.7 million (2020), whereas its average is $2.7 million.
  • Data for Mereo BioPharma Group's Receivables shows a peak YoY increased of 28.51% (in 2021) over the last 5 years.
  • Over the past 2 years, Mereo BioPharma Group's Receivables (Yearly) stood at $2.3 million in 2020, then rose by 28.51% to $3.0 million in 2021.